Treatment of diabetic complications with certain spiro-imidazolidine-diones
AssigneeAlcon Laboratories, Inc.
InventorBillie M. York, Jr.
Life of this patent
Estimating the term…
Abstract
Inhibition of aldose reductase activity with tetracyclic spiro-hydantoins, new tetracyclic spirohydantoin derivatives useful in the treatment of complications arising from diabetes mellitus, and a process for preparing spiro-imidazolidine-diones by reacting a mono- or di-fluorofluorene with an excess of oxygen and a tetralkyl- or arylalkyl-trialkyl-ammonium hydroxide are disclosed.
Claims2
A method for treating diabetic complications in mammals comprising administering an effective amount of spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione or pharmaceutically acceptable salt thereof having the formula ##STR27## where x,y, and z are selected from the group consisting of NH.sub.2, NO.sub.2, and CO.sub.2 H.
A method for treating diabetic complications in mammals comprising administering an effective amount of spiro-(fluoren-9',4'-imidazolidine)-2',5'-dione or pharmaceutically acceptable salt thereof having the formula ##STR28##
Dependencies are inferred from the claim text.